Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TSC1 |
Variant | Y185* |
Impact List | nonsense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | TSC1 Y185* results in a premature truncation of the Tsc1 protein at amino acid 185 of 1164 (UniProt.org). Y185* has not been characterized however, due to the effects of other truncation mutations downstream of Y185 (PMID: 11875047, PMID: 20547222), is predicted to lead to a loss of Tsc1 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
TSC1 mutant TSC1 inact mut TSC1 Y185* |
Transcript | NM_000368.5 |
gDNA | chr9:g.132921927G>T |
cDNA | c.555C>A |
Protein | p.Y185* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001406592.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406598.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
XM_017015098 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406606.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
XM_011518979.2 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
XM_017015097 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406599.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
XM_017015097.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001162426.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_000368.5 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_000368.4 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406608.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406600.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
XM_011518979.3 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406607.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406595.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
XM_017015096.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001162426.2 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406609.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_000368 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001162426 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406603.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
XM_017015096 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406593.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406601.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
XM_011518979 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406605.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
XM_005272211.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
XM_017015098.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
XM_005272211 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406596.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
XM_006717271.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
XM_006717271 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406594.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406604.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406597.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
NM_001406602.1 | chr9:g.132921927G>T | c.555C>A | p.Y185* | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TSC1 Y185* | transitional cell carcinoma | no benefit | Buparlisib | Case Reports/Case Series | Actionable | In a Phase II trial, Buparlisib (BKM120) treatment resulted in progressive disease in a patient with metastatic urothelial carcinoma harboring TSC1 Y185* (PMID: 32767682; NCT01551030). | 32767682 |